M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active, not recruiting NCT03517969

Summary

This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving M6620, carboplatin and docetaxel may work better in treating patients with metastatic castration-resistant prostate cancer compared to carboplatin and docetaxel alone.

Overall Response Rate

Radiologic measurements are performed every 3 cycles Up to 2 years. PSA measurements are performed every cycle up to 2 years · Participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate — Aragon Pharmaceuticals, Inc.
• Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery — Wake Forest University Health Sciences
• Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced P — National Cancer Institute (NCI)
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abirate — Janssen Research & Development, LLC
• Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Ola — National Cancer Institute (NCI)
• A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Pr — Janssen Research & Development, LLC

All trials